Home » Newsletters » BioWorld Science

BioWorld Science

March 24, 2011

View Archived Issues

Dominant negative CXCL8 (IL-8) mutant reduces renal allograft damage

Switching from agalsidase beta to agalsidase alfa feasible for Fabry's disease

Eisai receives European approval for Halaven in advanced breast cancer

Preliminary data from phase III trial support feasibility of rHuPH20-faciliated IGSC therapy

NeuroPhage plans phase I study of bacteriophage NPT-001 in Alzheimer's disease

Personalized peptide vaccine shows promise in patients with resistant urothelial carcinoma

Theravida's THVD-201 reduces symptoms of dry mouth in phase I trial in OAB, phase II study under way

Efficacy of botulinum toxin type A in idiopathic detrusor overactivity confirmed in large study

Potential new biomarker for chronic rhinosinusitis with nasal polyps identified / News in Context

Portsmouth Technologies patents novel hydroxamate histone deacetylase inhibitors

Synageva BioPharma receives funding for SBC-102 in lysosomal acid lipase deficiency

Cellular Dynamics and Roche form standard supply agreement for iCell Cardiomyocytes

OncoTherapy Science initiates gastric cancer vaccine trial in Singapore

Takeda launches Reminyl for dementia of the Alzheimer's type in Japan

Phase I/II results for InSite Vision's ISV-303 encouraging for cataract postsurgery pain

Xoma reports phase II data for XOMA-052 in type 2 diabetes

Starpharma completes all patient follow-up visits in phase II trial of VivaGel

SYGNIS to continue phase II AXIS 2 study of AX-200 in acute ischemic stroke

Ambrilia Biopharma enters into agreement with ZBx for PSP-94

Rexahn reaches 33% enrollment in phase IIb trial of Serdaxin in major depressive disorder

Takeda submits Japanese NDA for TAK-536 in hypertension

Phase III elvitegravir trial in HIV meets primary objective

Graceway receives Canadian approval for topical genital warts treatment Vyloma 3.75%

KaloBios begins phase I trial of anti-EphA3 monoclonal antibody in hematologic malignancies

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
SERCA inhibitor from Sumitomo shows promise for MSA-C treatment
BioWorld Science
At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Sumitomo Pharma Co....